Trial
NCT01498588
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
Eisai Inc.
Condition
Breast Neoplasms
Intervention
Eribulin
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-03